WALMART Forming a peak pattern. Correction possible.Walmart is technically bullish on the 1D outlook (RSI = 66.294, MACD = 1.320, ADX = 41.735) but has reached the top of the 18 month Channel Up. With the 1D RSI Double Topped inside the overbought zone, the current price is increasingly unstable and the rally since the December 11th 2023 HL unsustainable withouth a correction. The three main pullbacks inside the Channel Up have been within the -10.20% and -11.92% region. A new -10% correction would test the 0.236 Channel Fib and come close to the 1D MA200. That is our target (TP = 54.50).
## If you like our free content follow our profile to get more daily ideas. ##
## Comments and likes are greatly appreciated. ##
Stocktrading
PODDDoes look bullish. OverSold on daily, Golden pocket, KDJ Bullish.
If we go past my target or hold that level and not go down, it's full continuation of Bull for this stock.
Insulet (NASDAQ: PODD) stands as an innovative medical device company committed to enhancing the lives of individuals grappling with diabetes and related conditions through its groundbreaking Omnipod delivery system. PODD mission is deeply rooted in personal experiences, with many of us directly impacted by diabetes. They advocate for their customers, affectionately known as Podders, and the broader diabetes community.
"PANW" Palo Alto Networks - Insider TradingPANW is being bought by US Parliament member Nancy Pelosi, she bought twice in past month.
The current price is in perfect Golden Zone on Daily chart. If we go past ATH there is no actual telling where it will go up to next, we might just move sideways for now to reset RSI or even start moving up at any time. But it also might just drop down a bit.
Palo Alto Networks, a cybersecurity company that provides advanced firewall and cloud security solutions. Palo Alto Networks offers a range of products and services aimed at protecting organizations from cyber threats, including next-generation firewalls, cloud security, endpoint protection, and threat intelligence services. The company is known for its focus on innovation and its commitment to helping businesses secure their digital assets against evolving cyber threats.
TELSA STOCKHello, traders here is a summary of what the Telsa stock price may play out in the future as you can see the price has been respecting the trend lines and ended up creating a pattern (flag bullish pattern) so my prediction is that the price would break the above trend line and retest it then go up.
Canalaska $CVV up 50% on new findNew uranium find has pushed Canalaska up 50% in a day. Wow!
Downward trend channel formed in April 2021 and almost 3 years later it has broken out, pulled back and now rocketed with volume.
0.85 therefore seems achievable and 1.54 all time high could also be possible.
As ever, this is not a solicitation to trade. Do your own research and you decide all aspects of your own trading.
MPW's $4.60 Price Target After Bullish BreakoutTechnical Analysis
MPW has been showing some solid bullishness out of the buy zone. There has been 6 consecutive green weekly candles so far including this week. MPW is forming a bullish breakout above this light blue trendline and orange resistance zone. I think there will be a pullback at some point, but for now the trend is still bullish and $4.60 is the key price target on this move up.
Medical Properties Trust (MPW): Navigating Liquidity And Strategic Asset Management
Medical Properties Trust Inc. (NYSE: MPW) recently shared insights into its financial health and strategic direction during its fourth quarter 2023 earnings call. With a focus on creating significant liquidity and managing its diverse portfolio of healthcare facilities, the company outlined its plan to navigate through current challenges and capitalize on its strengths. This blog delves into the key takeaways from the earnings call, highlighting both the bullish and bearish aspects of MPW’s strategy and performance.
Strategic Initiatives For Enhanced Liquidity
MPW’s CEO, Edward Aldag Jr., unveiled a capital allocation strategy aimed at generating at least $2 billion in liquidity by 2024. This ambitious plan involves the sale of Australian facilities and hospitals to Prime Healthcare Services, showcasing MPW’s proactive approach to capital management. These strategic asset sales, alongside ongoing opportunities, underscore the company’s commitment to financial flexibility and growth.
Addressing Challenges With Optimism
Despite facing issues with Steward Health Care System’s cash collections, MPW remains optimistic. The company is actively working on re-tenanting Steward properties, reflecting confidence in its ability to manage tenant-related challenges effectively. Additionally, the improved performance of Prospect Medical Holdings adds a layer of positivity, reinforcing MPW’s diversified portfolio’s strength.
A Look At The Bearish And Bullish Highlights
Bearish Insights:
The distressed situation with Steward has necessitated strategic re-tenanting and asset sales to ensure consistent rent payments.
A significant write-down of $90 million for loans to Steward underscores the financial challenges faced.
Concerns remain for an operator within the cash accounting pool, projecting no financial support due to low coverage.
Bullish Perspectives:
Interest from multiple potential tenants for Steward properties indicates robust demand for MPW’s assets.
The company’s European and American portfolios, including Circle Health and Priory, demonstrate strong performance.
Prospect Medical Holdings’ turnaround contributes to the positive outlook, highlighting potential for growth.
Future Outlook And InvestingPro Insights
Looking ahead, MPW is poised to achieve its strategic objectives, bolstered by a focus on sustaining community health through acute care hospitals. The company’s strategic sales and financing plans aim to navigate the complex financial landscape successfully.
From an investment perspective, MPW presents a mixed bag of opportunities and challenges. According to InvestingPro data, the company boasts a market cap of $2.28 billion USD and an appealing dividend yield of 15.79%. The aggressive share buyback program and low Price / Book multiple suggest that MPW may be undervalued, offering potential for income generation and price appreciation.
Conclusion
Medical Properties Trust Inc. is at a pivotal point, with strategic initiatives in place to enhance liquidity and manage its portfolio effectively. While challenges remain, particularly with certain tenants, the company’s optimistic approach and strategic sales indicate a forward-looking perspective. For investors, MPW’s current valuation and dividend yield may offer attractive opportunities, especially for those focused on income generation and value investing. As MPW navigates its strategic path, its ability to adapt and capitalize on its strengths will be crucial in driving future success.
NVAX Bullish Breakout After Settlement of Gavi DisputeNVAX Technical Analysis
NVAX has been showing some solid bullishness since settling the Gavi dispute. NVAX is pumping out of the buy zone, and there has been a bullish breakout above the light blue resistance line. The key price target ahead is the green resistance line ($6.36), a yellow resistance zone ($8.20 to $8.46), and a red resistance line ($10.23). I have $3.54 to $3.93 as my new buy zone. I think there are likely to be more buy opportunities around there. For now the price is bullish and trending up.
Novavax Reaches Settlement With Gavi, Paving The Way Forward
In a significant development announced on February 22, Novavax, a key player in the COVID-19 vaccine market, has reached a settlement with Gavi, the Vaccine Alliance, resolving a contentious dispute over unfulfilled vaccine orders. This settlement marks a critical juncture for Novavax, alleviating financial uncertainties and setting the stage for future growth and collaborations.
The Dispute Resolution
Novavax has committed to repaying Gavi a minimum of $475 million, either in cash or through vaccine supplies, by the end of 2028. This agreement comes as a resolution to a conflict stemming from Novavax’s inability to deliver on a contract for up to 350 million doses of its COVID-19 vaccine, despite Gavi’s advance payment of $700 million in 2021 and 2022.
Impact On Novavax
The announcement led to a significant surge in Novavax’s stock price, which climbed by 23.2% to $4.91 following the news. This is a noteworthy rebound for the company, whose stock had previously plummeted by nearly 60% amid concerns over its operational viability. The settlement not only removes a major financial overhang but also enhances Novavax’s appeal as a business partner, according to CEO John Jacobs.
Settlement Terms
Under the terms of the settlement, Novavax has made an upfront payment of $75 million to Gavi, with additional payments of $80 million annually in quarterly installments scheduled through 2028. These payments can be adjusted if Gavi opts to receive vaccines instead of cash. The agreement also includes provisions for extra vaccine credits, potentially worth up to $225 million, should demand exceed the annual $80 million mark.
Strategic Implications For Novavax
The resolution of this dispute is pivotal for Novavax, offering a path to stabilize its financials and focus on future endeavors. CEO John Jacobs highlighted the settlement’s role in mitigating the risk of a substantial one-time payment and enabling better cash flow management. The estimated present value of the settlement ranges between $300 and $400 million, signaling a strategic financial recalibration for the company.
Looking Ahead
With new leadership at the helm of both Novavax and Gavi, this agreement signals a fresh start and a mutual focus on future collaborations and initiatives. Novavax is already eyeing new revenue streams, with plans to introduce a combination COVID-flu vaccine by 2026 and capitalize on a malaria vaccine developed in partnership with the Serum Institute of India. These initiatives, coupled with significant cost reductions and operational streamlining, underscore Novavax’s commitment to overcoming past challenges and seizing future opportunities.
Conclusion
In conclusion, the settlement between Novavax and Gavi not only resolves a major dispute but also highlights the resilience and strategic pivoting of Novavax amidst the complexities of the global vaccine landscape. As the company navigates beyond its COVID-centric phase, this development offers promising insights into its potential for innovation, growth, and partnerships in the years to come.
PSNY Potential bullish rideReasons for bullish bias:
- Falling wedge with prominent bullish divergence
- Safe entry at breakout of LH for confirmation
- Targets till projection
Entry Level(Buy stop): 2.71
Stop Loss Level: 1.48
Take Profit Level 1: 3.94
Take Profit Level 2: 5.17
Take Profit Level 3: 6.4
How will AEP react to it's results on Feb 27th? We are taking a short position on AEP before it's results.
1) There is a nice deep crab pattern on H4
2) The H4 is overbought
3) There is a double top
4) Divergence is present
This is a purely technical view and we expect the news to be bearish for AEP.
Stop loss above 84.50
Target 73.
DIAL.N0000Wait for a pullback
Buy Zone - 8.7 to 8.9
Disclaimer: The information and analysis provided in this publication are for educational purposes only and should not be construed as financial advice or recommendations to buy, sell, or hold any securities. The author and TradingView are not responsible for any investment decisions made based on the content presented herein. Always consult a financial professional before making any investment decisions.
NVDA - The Trend Is Your FriendPretty incredible chart. This price action will be talked about for years. Where will it end? How will it end? These are not questions I know how to answer. The great thing is I don't have to know the answers to these questions to profit MAJORLY from the price action. Everything I need to know is reflected in the price action.
The trend is your friend (until the end). #NVDA
JSW INFRA - SHORT TERM & LONG TERM SEEMS GOODCan enter at CMP 224
If falls again you need to average at 200 level
Targets - 245,280+
Disclaimer - All information on this page is for educational purposes only,
we are not SEBI Registered, Please consult a SEBI registered financial advisor for your financial matters before investing And taking any decision. We are not responsible for any profit/loss you made.
Request your support and engagement by liking and commenting & follow to provide encouragement
HAPPY TRADING 👍
EMAMI LTD SWING TRADE FOR COMING 3-6 MONTHS1.Bullish Chart Pattern is Forming on Higher TF of Weekly & Monthly
2. Kind Of H&S Pattern is getting structured
3. Currently Trading at Monthly Demand Zone of 450-460
4. Filled a gap on Daily TF
5. Bullish Engulfing on Daily TF with Heavy Volume
6. Fundamentals and company business is intact and showing growth consistently with Profits
7. Share Holding Pattern is also strong among big players & Institutions.
Buy @ 460-465
Stop Loss - 445
Target- 1st- 600 2nd- 700 & 3rd & Final- 900
View Holding For Next 3-9 Months
SEDG forming double bottomsReasons for bullish bias:
- Price is at strong support
- Price formed double bottoms on weekly
- Entry at neckline breakout for further confirmation
- Strong bullish divergence
Entry Level(Buy stop): 106.25
Stop Loss Level: 58.17
Take Profit Level 1: 154.33
Take Profit Level 2: Open